Other Income	12 Months Ended
Sep. 30, 2022
Other Income
Other Income	Note 4 Other Income *Grant income* During the year ended September 30, 2022, the Company received $0 (2021: $497,931; 2020: $0) of a $995,862 research grant awarded during the year ended September 30, 2021, by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX^®2-73 related to Parkinson’s disease. The grant income is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During the year ended September 30, 2022, the Company recognized $Nil 0 (2021: $54,100; 2020: $Nil 0) of this grant on its statements of operations within grant income. At September 30, 2022 an amount of $443,831 (2021: $443,831) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. During the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was received in equal quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome. The grant income was deferred when received and amortized to other income as the related research and development expenditures were incurred. During the year ended September 30, 2020, the Company recognized $149,888 of this grant on its statement of operations as a component of other income. At September 30, 2020, the Company had recognized the full amount of grant funding. *Research and development incentive income* Research and development incentive income represents income earned by the Company’s Australian subsidiary, of the Australian research and development tax incentive credit (the “tax incentive credit”). During the year ended September 30, 2022, the Company recorded research and development incentive income of $3,323,011 (AUD 4,468,246) (2021: $4,547,099 (AUD 6,068,993); 2020: $4,375,025 (AUD 6,392,266)) in respect of the tax incentive credit for eligible research and development expenses incurred during the year. The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant data available. Although the Company believes that it complies with all the relevant conditions of the program, as a matter of course, the Company may be subject to pre-issue review or audit by the ATO and, the ATO may have different interpretations of certain eligibility requirements. Currently, the Company’s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.

Other Income

12 Months Ended

Sep. 30, 2022

Note 4 Other Income

Grant income

During the year ended September 30, 2022, the Company received $0 (2021: $497,931; 2020: $0) of a $995,862 research grant awarded during the year ended September 30, 2021, by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX^®2-73 related to Parkinson’s disease.

The grant income is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During the year ended September 30, 2022, the Company recognized $Nil 0 (2021: $54,100; 2020: $Nil 0) of this grant on its statements of operations within grant income. At September 30, 2022 an amount of $443,831 (2021: $443,831) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to other income.

During the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was received in equal quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.

The grant income was deferred when received and amortized to other income as the related research and development expenditures were incurred. During the year ended September 30, 2020, the Company recognized $149,888 of this grant on its statement of operations as a component of other income. At September 30, 2020, the Company had recognized the full amount of grant funding.

Research and development incentive income

Research and development incentive income represents income earned by the Company’s Australian subsidiary, of the Australian research and development tax incentive credit (the “tax incentive credit”).

During the year ended September 30, 2022, the Company recorded research and development incentive income of $3,323,011 (AUD 4,468,246) (2021: $4,547,099 (AUD 6,068,993); 2020: $4,375,025 (AUD 6,392,266)) in respect of the tax incentive credit for eligible research and development expenses incurred during the year.

The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant data available. Although the Company believes that it complies with all the relevant conditions of the program, as a matter of course, the Company may be subject to pre-issue review or audit by the ATO and, the ATO may have different interpretations of certain eligibility requirements. Currently, the Company’s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.